FibroGen dials up a $155M IPO; AstraZeneca partners with University of Manchester;

@FierceBiotech: ICYMI earlier this month, check out this year's Women in Biotech, featuring women at the top of their field. Feature | Follow @FierceBiotech

@JohnCFierce: If $SNY's board did turn to Soriot ($AZN) to try and recruit him for CEO, it shows they don't really know what they're doing. | Follow @JohnCFierce

@DamianFierce: Six of Cleveland Clinic's Top 10 Medical Innovations are drugs, and here's a bunch of words on them. Article | Follow @DamianFierce

@EmilyMFierce:  Good read on Sarepta and the issue of compassionate use. More from Bloomberg BusinessWeek | Follow @EmilyMFierce

> FibroGen, a 2013 Fierce 15 honoree, has raised the stakes of its planned IPO, looking to raise up to $155 million by offering 8.2 million shares at between $16 and $19 each. The biotech is developing a treatment for idiopathic pulmonary fibrosis (IPF), hoping to contend with giants Roche ($RHHBY) and Boehringer Ingelheim. More

> AstraZeneca ($AZN) has partnered up with the University of Manchester in a 5-year collaboration designed to investigate new drug delivery technologies. News

> Chimerix ($CMRX) is raising $105 million through a public offering, money it plans to spend on R&D, while Regulus Therapeutics ($RGLS) has its eye on about $70 million through a stock sale of its own, supported by major shareholder Isis Pharmaceuticals ($ISIS). Chimerix | Regulus

Medical Device News

@FierceMedDev: Ken Drazan of JNJ Innovation talks future of med tech. Editor's Corner | Follow @FierceMedDev

@VarunSaxena2: ICYMI yesterday: Rating agencies likely to cut Medtronic's credit rating due to looming merger with Covidien. Story | Follow @VarunSaxena2

@EmilyWFierce: ICYMI: Check out @FierceMedDev's list of the most influential women in the med tech industry here. Feature | Follow @EmilyWFierce

@MichaelGFierce: @HarvardResearch team uses stem cells to deliver toxic doses to #cancer cells. More | Follow @MichaelGFierce

> Chinese government urges hospitals to buy local devices. News

> Nintendo developing cloud-based sleep-monitoring device amid market growth. Story

> GE Healthcare opens first health tech incubator. Article

Pharma News

@FiercePharma: CEO-hunting Sanofi tried to tempt AstraZeneca's Soriot: Bloomberg. Article | Follow @FiercePharma

@EricPFierce: ICYMI from FiercePharmaManufacturing: Sanofi says it doesn't not know why its flu strains grew slowly, holding up vax deliveries in U.S. Article | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Pfizer beats out Novartis with FDA MenB nod. FierceVaccines article | Follow @CarlyHFierce

> Novo Nordisk quells diabetes pricing fears with 2015 growth forecast. More

> Ex-Sanofi CEO Viehbacher in line for up to $7.8M cash payoff. Report

Vaccines News

> South African trial renews hopes in failed HIV vaccine combo. More

> Dendreon's Provenge at the center of CMS insider trading probe. Item

> Pfizer beats out Novartis with FDA MenB nod. Story

> Ebola update: Novavax testing nanoparticle jab, Glaxo gets EMA's advice. More

> Novartis officially bows out of vaccines with flu sale to CSL. Article

Pharma Manufacturing News

> Turkish man sent to prison for smuggling fake Avastin into U.S. Item

> Novo hiring 90 workers for its new plant in New Hampshire. News

> More heat applied to Genentech CEO for supply-chain decision on cancer drugs. Report

> Lilly offers behind-the-scenes look at its decade-long tech transfer for TB drugs. Story

> Serum Institute of India to invest $160M in new plant. Article

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

U.K.-based alpha-synuclein biotech Wren will partner with Japanese pharma Eisai to seek out new ways of targeting neuro disorders.

As Moderna continues to drip-feed the latest data from its late-stage COVID-19 vaccine effort, it has updated the shot’s efficacy figure.

Two research teams have discovered drug combinations that may make it possible to translate CAR-T cell therapies to solid tumors.